May 11, 2022 10:07 AM EDT
Bioregnum
R&D

The col­lapse of SKY­SCRAPER-01 is cast­ing a pall over all the TIG­ITs. Are we in for an­oth­er I/O fi­as­co?

The first time Roche re­port­ed a fail­ure for its sweep­ing Phase III pro­gram for the TIG­IT con­tender tiragolum­ab a cou­ple of months ago, quite a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times